Physician profile
Blake Larose
NPI 1366129769
$5,486.53
in general payments reported to CMS, 2019-2025
35 companies · $3,274 in 2025
The $3,274 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $196 · 2024: $2,016 · 2025: $3,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,387 · Education: $99.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.15 |
| Education | $99.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $844.60 | 2024-2025 | Farxiga, Breztri |
| Abbvie INC. | $766.29 | 2023-2025 | |
| Novo Nordisk INC | $388.26 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $367.49 | 2025 | Fanapt |
| Pfizer INC. | $311.20 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $280.45 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $230.51 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.13 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $213.29 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $200.48 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $194.97 | 2023-2025 | Veozah |
| Esperion Therapeutics, INC. | $141.89 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $118.54 | 2023-2025 | |
| Amgen INC. | $115.44 | 2024-2025 | Evenity, Prolia, Repatha |
| Madrigal Pharmaceuticals | $101.21 | 2025 | Rezdiffra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $89.70 | 2024-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $82.27 | 2024-2025 | Xyosted |
| Lundbeck LLC | $81.66 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $77.24 | 2025 | Trintellix |
| Lilly USA, LLC | $77.08 | 2024-2025 | Mounjaro, Zepbound |
| Corium, LLC | $73.92 | 2025 | Azstarys |
| Phathom Pharmaceuticals, INC. | $71.40 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $68.90 | 2024-2025 | |
| Tolmar, INC. | $54.74 | 2024-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.05 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $38.29 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $35.54 | 2024-2025 | Spravato |
| Shield Therapeutics INC | $34.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.72 | 2024-2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $30.27 | 2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $26.87 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $21.15 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $18.86 | 2024 | Capvaxive |
| Viatris Specialty LLC | $17.24 | 2025 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.80 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Larose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.